Gastroenterology Daily Report: 01/26/2024

A phase 3 clinical trial investigated the effect of vedolizumab in patients with moderate to severe Crohn's disease and included a substudy using magnetic resonance enterography (MRE) to assess transmural inflammation. Vedolizumab was administered intravenously at weeks 0, 2, and 6, then every 8 weeks for 26 or 52 weeks (1). The study found a reduction in transmural inflammation, evidenced by decreased bowel edema and wall thickness in MRE images evaluated in 27 patients at week 26 and 13 patients at week 52. The results highlight the impact of vedolizumab on transmural inflammation in Crohn's disease and demonstrate the feasibility of using MRE in multicenter clinical trials. Trial registration: ClinicalTrials.gov NCT02425111 and EU Clinical Trials Register EudraCT 2014-003509-13.

Reference

Rimola J, Colombel JF, Bressler B, Adsul S, Siegelman J, Cole PE, Lindner D, Danese S. Magnetic Resonance Enterography Assessment of Transmural Healing with Vedolizumab in Moderate to Severe Crohn's Disease: Feasibility in the VERSIFY Phase 3 Clinical Trial. Clin Exp Gastroenterol. 2024 Jan 27;17:9-23. doi: 10.2147/CEG.S429039. PMID: 38298861; PMCID: PMC10829592.